BioDlink International (HKG:1875) recorded an attributable loss of 3.4 million yuan in the nine months ended Sept. 30, compared with an attributable profit of 35.4 million yuan a year prior, a Tuesday Hong Kong bourse filing said.
The biopharmaceutical company's revenue for the three quarters fell 23% to 621.7 million yuan from 809 million yuan in the year-ago period.